Late-Onset Sjögren disease: A different clinical entity?
Keywords:
Sjögren’s disease, elderly-onset, clinical and serological features, interstitial lung diseaseAbstract
Background and aim: Sjögren’s disease(SjD) exhibits heterogeneous clinical phenotypes influenced by age at onset. This study aimed to evaluate the impact of onset age on the clinical and serological characteristics of SjD in a Turkish cohort.
Methods: We retrospectively analyzed 411 patients diagnosed with SjD between 2013 and 2024, fulfilling the 2002 AECG or 2016 ACR/EULAR criteria. Patients were classified as young-onset (<40 years; YoSjD), adult-onset (40–60 years; AoSjD), or elderly-onset (>60 years; EoSjD). Demographic, clinical, laboratory, and treatment characteristics were compared among groups.
Results: The cohort comprised predominantly females (93.4%) with a median age of 55 years. RF positivity was significantly higher in EoSjS (35.5%) compared to YoSjD (27.9%) and AoSjD (19.2%, p=0.007). Inflammatory markers (ESR, CRP) were more frequently elevated in EoSjD. Interstitial lung disease (ILD) prevalence was highest in EoSjD (25.8%, p<0.05), particularly in males. Artropathy was more frequent in EoSjD (80.6%) and YoSjD (76%) than in AoSjD (64.5%, p=0.007). Anemia was more common in EoSjD (20.4%, p=0.040). Hydroxychloroquine was widely used (86.6%), with glucocorticoid and azathioprine use significantly higher in EoSjD.
Conclusions: Elderly-onset SjD demonstrates a distinct phenotype characterized by higher ILD prevalence, increased RF positivity, greater inflammatory activity, and more frequent artropathy and anemia compared to younger-onset groups. These findings highlight the need for age-tailored diagnostic vigilance, proactive ILD screening, and cautious use of immunosuppressants in older patients. Prospective multicenter studies are warranted to refine management strategies in this subgroup.
References
1. Fox RI Sjögren's syndrome. Lancet. 2005;366(9482):321-331. doi:10.1016/S0140-6736(05)66990-5
2. Ramos-Casals M, Baer AN, Brito-Zerón MDP et al. 2023 International Rome consensus for the nomenclature of Sjögren disease. Nature Reviews Rheumatology. 2025;21(7):426-37. doi:10.1038/s41584-025-01268-z
3. Brito-Zerón P, Acar-Denizli N, Zeher M et al. Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. Annals of the rheumatic diseases. 2017;76(6):1042-50. doi: 10.1136/annrheumdis-2016-209952
4. Brito-Zerón P, Acar-Denizli N, Zeher M et al. Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine(Baltimore). 2002;81(4):270-80. doi: 10.1097/00005792-200207000-00003
5. Beydon M, McCoy S, Nguyen Y, Sumida T, Mariette X, Seror R Epidemiology of Sjögren syndrome. Nature Reviews Rheumatology. 2024;20(3):158-69. doi:10.1038/s41584-023-01057-6.
6. Haugen A, Peen E, Hulten B et al. Estimation of the prevalence of primary Sjögren's syndrome in two age‐different community‐based populations using two sets of classification criteria: the Hordaland Health Study. Scandinavian journal of rheumatology. 2008;37(1):30-4. doi: 10.1080/03009740701678712
7. Pillemer SR, Matteson EL, Jacobsson LT et al. Incidence of physician-diagnosed primary Sjögren syndrome in residents of Olmsted County, Minnesota. Mayo Clinic Proceedings; 2001;76(6):593-9. doi:10.4065/76.6.593
8. Manzo C, Maslinska, M Primary Sjögren’s syndrome in the elderly: does age of onset make a difference. EMJ Rheumatol. 2018;5(1):75-82. doi:10.33590/emjrheumatol/10313472
9. Luo J, Zhang Y, Chen J et al. Distinct clinical phenotypes of primary Sjögren’s syndrome differ by onset age: a retrospective study of 742 cases and review of the literature. Clin Exp Rheumatol. 2022;40(12):2373-80. doi:10.55563/clinexprheumatol/b4z1qu
10. Retamozo S, Acar-Denizli N, Horváth IF et al. Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. Clin Exp Rheumatol. 2021;39 Suppl 133(6):S166-S174. doi:10.55563/clinexprheumatol/egnd1i
11. Radovic S, Vrljes A, Dasic A, Stojanovic M, Miskovic R Diagnostic and therapeutic challenges in elderly-onset Sjögren’s syndrome. Anti-Aging East. Eur. 2025;4(1):26-33. doi:10.56543/aaeeu.2025.4.1.04
12. Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554-8. doi:10.1136/ard.61.6.554
13. Shiboski CH, Shiboski SC, Seror R et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69(1):35-45. doi:10.1002/art.39859
14. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913. doi: 10.1183 / 13993003.01913-2018
15. Botsios C, Furlan A, Ostuni P, et al. Elderly onset of primary Sjögren's syndrome: clinical manifestations, serological features and oral/ocular diagnostic tests. Comparison with adult and young onset of the disease in a cohort of 336 Italian patients. Joint Bone Spine. 2011;78(2):171-4. doi:10.1016/j.jbspin.2010.05.008
16. Ramos-Casals M, Cervera R, Font J et al. Young onset of primary Sjögren's syndrome: clinical and immunological characteristics. Lupus. 1998;7(3):202-6 doi:10.1191/0961203986789 20019
17. Scherer HU, Häupl T, Burmester GR The etiology of rheumatoid arthritis. J Autoimmun. 2020;110:102400. doi:10.1016/j.jaut.2019.102400
18. Bouma HR, Bootsma H, van Nimwegen JF, et al. Aging and immunopathology in primary Sjögren's syndrome. Curr Aging Sci. 2015;8(2):202-13. doi:10.2174/1874609808666150727112 826
19. Anquetil C, Hachulla E, Machuron F, et al. Is early-onset primary Sjögren's syndrome a worse prognosis form of the disease? Rheumatology (Oxford). 2019;58(7):1163-1167. doi:10.1093/ rheumatology/key392
20. Moerman RV, Bootsma H, Kroese FG Vissink A Sjögren's syndrome in older patients: aetiology, diagnosis and management. Drugs Aging. 2013;30(3):137-153. doi:10.1007/s40266-013-0050-7
21. Flament T, Bigot A, Chaigne B, Henique H, Diot E, Marchand-Adam S Pulmonary manifestations of Sjögren's syndrome. Eur Respir Rev. 2016;25(140):110-23. doi:10.1183/ 16000617.0011-2016
22. Luppi F, Sebastiani M, Silva M et al. Interstitial lung disease in Sjögren's syndrome: a clinical review. Clin Exp Rheumatol. 2020;38 Suppl 126(4):291-300. PMID: 33095142
23. Liu Z, Liang Q, Ren Y, et al. Immunosenescence: molecular mechanisms and diseases. Signal Transduct Target Ther. 2023;8(1):200. doi:10.1038/s41392-023-01451-2
24. Nakanishi K, Kinjo M AB0463 Clinical characteristics of elderly patients with primary Sjögren's syndrome. Ann Rheum Dis. 2016;75(Suppl 2):1064.3. doi:10.1136/annrheumdis-2016-eular.3558
25. Konak HE, Atalar E, Hezer H et al. Interstitial lung disease in primary Sjögren’s syndrome: risk factors for occurrence and radiographic progression. Sarcoidosis Vasc Diffuse Lung Dis. 2024;41(3):e2024035. doi:10.36141/svdld.v41i3.15548
26. Berardicurti O, Marino A, Genovali I et al. Interstitial lung disease and pulmonary damage in primary Sjögren's syndrome: a systematic review and meta-analysis. J Clin Med. 2023;12(7):2586. doi:10.3390/jcm12072586
27. Ozsoy Z, Ozdemırel TŞ, Ensarıoğlu K et al. Evaluation of patients diagnosed with primary Sjogren’s syndrome with and without pulmonary involvement. Sarcoidosis Vasc Diffuse Lung Dis. 2025;42(3):17364. doi:10.36141/svdld.v42i3.17364.
28. Brito-Zerón P, Retamozo S, Ramos-Casals M Phenotyping Sjögren's syndrome: towards a personalised management of the disease. Clin Exp Rheumatol. 2018;36 Suppl 112(3):198-209. PMID:30156544.
29. Manganelli P, Fietta P, Quaini F Hematologic manifestations of primary Sjögren's syndrome. Clin Exp Rheumatol. 2006;24(4):438-48. PMID:16956437
30. Yıldız F, Gökmen O Haematologic indices and disease activity index in primary Sjogren's syndrome. Int J Clin Pract. 2021;75(3):e13992. doi:10.1111/ijcp.13992.
31. Kahraman Denizhan T, Oguz Kokoglu E, Kızıltepe M, et al Evaluation of the incidence of malignancy in Sjögren's syndrome: a single-center study from Turkey. Cureus. 2025;17(3):e81219. doi:10.7759/cureus.81219
32. Zhong H, Liu S, Wang Y, et al Primary Sjögren's syndrome is associated with increased risk of malignancies besides lymphoma: a systematic review and meta-analysis. Autoimmun Rev. 2022;21(5):103084. doi:10.1016/j.autrev.2022.103084.
33. Segal B, Carpenter A, Walk D Involvement of nervous system pathways in primary Sjögren's syndrome. Rheum Dis Clin North Am. 2008;34(4):885-906, viii. doi:10.1016/ j.rdc. 2008.08.001.
34. Tobón GJ, Pers JO, Devauchelle-Pensec V, Youinou P Neurological disorders in primary Sjögren's syndrome. Autoimmune Dis. 2012;2012:645967. doi:10.1155/2012/645967
35. Lazarus MN, Robinson D, Mak V, Møller H, Isenberg DA Incidence of cancer in a cohort of patients with primary Sjogren's syndrome. Rheumatology (Oxford). 2006;45(8):1012-5. doi:10. 1093/rheumatology/kei281.
36. Voulgarelis M, Ziakas PD, Papageorgiou A, Baimpa E, Tzioufas AG, Moutsopoulos HM Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome. Medicine (Baltimore). 2012;91(1):1-9. doi:10.1097/MD.0b013e31824125e4.
37. Firestein GS, Budd RC, Gabriel SE, McInnes IB, O'Dell JR Kelley and Firestein's textbook of rheumatology. 10th ed. Elsevier; 2016.
38. Price EJ, Benjamin S, Bombardieri M, et al British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease. Rheumatology (Oxford). 2025;64(2):409-439. doi:10.1093/rheumatology/keae152.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Celil Barlas Cengiz, Tuğba Kahraman Denizhan, Hüseyin Kaplan, Emel Oğuz Kökoğlu, Melih Kızıltepe, Burcu Eren Cengiz, Hanife Oğuz, Abdurrahman Soner Şenel
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
